Eli Lilly and Company (NYSE:LLY) Shares Bought by Allen Mooney & Barnes Investment Advisors LLC

Allen Mooney & Barnes Investment Advisors LLC increased its stake in Eli Lilly and Company (NYSE:LLY) by 2.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,248 shares of the company’s stock after acquiring an additional 127 shares during the period. Allen Mooney & Barnes Investment Advisors LLC’s holdings in Eli Lilly and Company were worth $4,052,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of LLY. Rockland Trust Co. boosted its holdings in Eli Lilly and Company by 2.2% in the fourth quarter. Rockland Trust Co. now owns 11,671 shares of the company’s stock valued at $9,010,000 after acquiring an additional 253 shares during the last quarter. Fifth Third Wealth Advisors LLC raised its holdings in shares of Eli Lilly and Company by 14.6% in the 4th quarter. Fifth Third Wealth Advisors LLC now owns 13,287 shares of the company’s stock worth $10,257,000 after purchasing an additional 1,694 shares during the period. Community Trust & Investment Co. lifted its stake in shares of Eli Lilly and Company by 37.4% in the 4th quarter. Community Trust & Investment Co. now owns 17,251 shares of the company’s stock valued at $13,318,000 after purchasing an additional 4,696 shares in the last quarter. Floyd Financial Group LLC purchased a new stake in shares of Eli Lilly and Company during the 4th quarter worth about $1,106,000. Finally, Pines Wealth Management LLC acquired a new stake in Eli Lilly and Company during the 4th quarter worth approximately $2,839,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

LLY has been the subject of several research reports. Truist Financial boosted their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research note on Thursday, October 10th. Barclays cut their price objective on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research report on Thursday, October 31st. Sanford C. Bernstein initiated coverage on Eli Lilly and Company in a research report on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 target price for the company. Bank of America reiterated a “buy” rating and set a $997.00 target price on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Finally, StockNews.com upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, January 1st. Four investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $1,002.22.

Eli Lilly and Company Trading Up 0.2 %

NYSE:LLY opened at $746.42 on Thursday. The company has a market cap of $708.59 billion, a PE ratio of 80.69, a P/E/G ratio of 2.99 and a beta of 0.41. The business’s 50 day moving average is $784.63 and its two-hundred day moving average is $857.48. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. Eli Lilly and Company has a 52 week low of $612.70 and a 52 week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The firm had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. During the same quarter last year, the business earned $0.10 earnings per share. The business’s revenue for the quarter was up 20.4% compared to the same quarter last year. On average, analysts predict that Eli Lilly and Company will post 13.18 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.80%. The ex-dividend date of this dividend is Friday, February 14th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. Eli Lilly and Company’s dividend payout ratio is currently 64.86%.

Eli Lilly and Company declared that its Board of Directors has initiated a stock repurchase plan on Monday, December 9th that permits the company to buyback $15.00 billion in shares. This buyback authorization permits the company to buy up to 2% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s board believes its stock is undervalued.

Insiders Place Their Bets

In related news, CAO Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the transaction, the chief accounting officer now owns 5,480 shares in the company, valued at $4,402,522.40. The trade was a 14.11 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.13% of the stock is currently owned by corporate insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.